Item 2.02 Results of Operations and Financial Condition.
Charles P. Theuer, M.D., Ph.D., President and Chief Executive Officer of TRACON
Pharmaceuticals, Inc. ("TRACON"), and other executive officers will be
presenting information that includes an estimate of TRACON's December 31, 2019
cash, cash equivalents and short-term investments and outstanding debt principal
balances, at various upcoming meetings beginning January 6, 2020. The
information is attached as Exhibit 99.1 to this Current Report on Form 8-K.
Item 7.01 Regulation FD Disclosure.
Charles P. Theuer, M.D., Ph.D., and other executive officers will be presenting
the information attached as Exhibit 99.1 to this Current Report on Form 8-K at
various upcoming meetings beginning January 6, 2020.
By furnishing this information, TRACON makes no admission as to the materiality
of any information in this report. The information contained in this report and
the exhibit hereto is intended to be considered in the context of TRACON's
filings with the Securities and Exchange Commission and other public
announcements that TRACON makes, by press release or otherwise, from time to
time. TRACON undertakes no duty or obligation to publicly update or revise the
information contained in this report or the exhibit hereto, although it may do
so from time to time as its management believes is appropriate. Any such
updating may be made through the filing of other reports or documents with the
Securities and Exchange Commission, through press releases or through other
public disclosure.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.
Description
99.1 Corporate Presentation, dated January 2020--------------------------------------------------------------------------------
© Edgar Online, source Glimpses
TRACON PHARMACEUTICALS, INC. 
